-+ 0.00%
-+ 0.00%
-+ 0.00%

Cytokinetics' Aficamten Reduces Heart Muscle Thickening in Non-Obstructive HCM Trial

PUBT·11/09/2026 12:35:07
Cytokinetics' Aficamten Reduces Heart Muscle Thickening in Non-Obstructive HCM Trial
  • Cytokinetics announced new aficamten findings presented at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions held with the American Heart Association’s 2026 sessions.
  • ACACIA-HCM analyses showed favorable cardiac remodeling in non-obstructive hypertrophic cardiomyopathy, with improved patient-reported symptoms and quality of life versus placebo.
  • Patient-reported benefits increased with longer treatment but faded following withdrawal.
  • FOREST-HCM found transient, reversible heart-pumping dysfunction during long-term treatment for obstructive disease, with no associated heart failure hospitalizations or deaths.
  • Aficamten, marketed as MYQORZO, is approved for symptomatic obstructive disease; ACACIA-HCM evaluated its potential in non-obstructive disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090730PRIMZONEFULLFEED9872899) on November 09, 2026, and is solely responsible for the information contained therein.